Results 61 to 70 of about 25,789 (212)

Clinical and Prognostic Impact of low DLco values in patients with GOLD I COPD.

open access: yesChest, 2021
J. de-Torres   +13 more
semanticscholar   +1 more source

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18–59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real‐Life Series From Southern Italy Cancer Centers

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 174-184, February 2026.
ABSTRACT BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. Young adults and adults (Ya&A) were the most common patients treated with BV + AVD in clinical trials but have not been studied in non‐trial settings. We conducted a real‐life study in secondary and tertiary cancer centers to evaluate the PFS in 18–59 years aged ...
Marco Picardi   +28 more
wiley   +1 more source

A Case of Atrial Septal Defect Unveiled by the Treatment for Pulmonary Arterial Hypertension

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT We present a case of a 51‐year‐old woman with atrial septal defect (ASD) masked by pulmonary arterial hypertension (PAH). Three months after PAH treatment with a combination of endothelin receptor antagonist and phosphodiesterase five inhibitor, the transthoracic echocardiography revealed left‐to‐right shunting through a secundum ASD.
Takaaki Fujii   +12 more
wiley   +1 more source

The evaluation of DLCO changes in patients with relatively higher lung shunt fractions receiving TARE

open access: gold, 2022
Ceren Ozge Engur   +8 more
openalex   +2 more sources

Knowledge Gaps and Controversies on Cardiopulmonary Exercise Testing in the Assessment of Pulmonary Vascular Disease: An Official Statement of the Pulmonary Vascular Research Institute Exercise and Right Ventricular Function Task Force

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Exercise testing has long been essential for evaluating diagnosis, prognosis, and functional status in pulmonary hypertension (PH). Recent advances have clarified its role in defining reference values and prognostic markers. Nonetheless, substantial knowledge gaps persist regarding the implementation of invasive cardiopulmonary exercise ...
Aaron B. Waxman   +20 more
wiley   +1 more source

Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease

open access: yesPulmonary Circulation, Volume 16, Issue 1, January 2026.
ABSTRACT Pulmonary hypertension (PH) associated with left heart disease (LHD‐PH) and pulmonary hypertension associated with chronic lung disease (CLD‐PH) are the most common PH subtypes but lack effective treatments. In a prospective cohort study, 90 patients (39 LHD‐PH, 51 CLD‐PH) with severe disease [pulmonary vascular resistance (PVR) > 5 Wood units
Roela Sadushi‐Koliçi   +8 more
wiley   +1 more source

Marked Reversibility of Functional Small Airway Disease Following Reduction of Hazardous Inhalational Exposure: A PRM CT Case Report

open access: yesRespirology Case Reports, Volume 14, Issue 1, January 2026.
Serial parametric response mapping (PRM)‐computed tomography revealed dynamic changes in PRM‐functional small airway disease with occupational exposure, highlighting PRM's utility for detecting and monitoring small airway disease. ABSTRACT We report a case illustrating the role of parametric response mapping (PRM) in detecting and monitoring small ...
Yeun Ho Lee   +4 more
wiley   +1 more source

Busting the Myths of DLco for Pulmonary Trainees: Isolated Reductions in DLco and the Relationship with VA

open access: yesJournal of Respiration
Background: DLco remains one of the most commonly performed tests in the pulmonary lab. An isolated reduction in DLco is a unique abnormality with specific differentials when evaluating a patient with dyspnea. There remains a significant misunderstanding amongst young pulmonologists and pulmonary trainees regarding DLco and its relationship with ...
Ahmad Raza   +4 more
openaire   +1 more source

Home - About - Disclaimer - Privacy